Author Archives: Steve Bryson PhD

CSL Plasma Donates $125K to American Red Cross for Disaster Relief

CSL Plasma has donated $125,000 to the American Red Cross to support recovery and relief efforts following disasters in the U.S., including tornadoes, hurricanes, wildfires, residential fires, and floods. These disasters can affect areas where plasma donors live and where employees involved in the manufacturing of plasma-derived therapies…

Enrollment Opens in HAERMONY Trial to Test HAE Gene Therapy

Enrollment is open for the open-label, Phase 1/2 HAERMONY trial to evaluate the safety and effectiveness of BMN 331, an investigational gene therapy for hereditary angioedema (HAE). The trial’s sponsor, BioMarin Pharmaceutical, plans to recruit about 34 adults with type 1 or type 2 HAE at one site…

KVD900 Rapidly Suppresses Kallikrein, Phase 1 Studies Show

KVD900, an investigational on-demand therapy for hereditary angioedema (HAE), rapidly and nearly completely suppressed kallikrein and was generally safe and well tolerated in healthy volunteers, according to Phase 1 studies. These findings, which have since been confirmed in a Phase 2 trial, supported the planned launch of…

Orladeyo Sustainably Lowers HAE Attack Rates, Trial Data Show

Orladeyo (berotralstat) reduced the frequency of swelling attacks in people with hereditary angioedema (HAE) and improved their quality of life over the course of one year, according to the latest findings from the long-term APeX-S trial. The approved oral medication also was able to sustainably lower HAE attack…

Catabasis, Now Renamed Astria, Working Toward HAE Trial Launch

Astria Therapeutics is the new name of the company that’s developing STAR-0215, an investigational kallikrein-inhibitor previously known as QLS-215, for the treatment of hereditary angioedema (HAE). Formerly called Catabasis Pharmaceuticals, the company said it changed its name to reflect its pledge of having patients serve as its guiding…

Oral On-demand KVD900 Rapidly Reduces HAE Attack Severity

KVD900, an oral experimental on-demand treatment for swelling episodes caused by hereditary angioedema (HAE), safely and significantly reduced the severity of attacks and shorted the time to improvement, which was maintained for 24 hours, according to Phase 2 trial data.  “Our goal is to provide the best outcome…